Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer reiterated a Buy rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and maintained a $50 price target.
February 22, 2024 | 5:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterated a Buy rating on Rhythm Pharmaceuticals and maintained a $50 price target.
The reiteration of a Buy rating and maintenance of a $50 price target by a reputable analyst like Joseph Stringer from Needham is likely to instill confidence among investors and could positively influence Rhythm Pharmaceuticals' stock price in the short term. Analyst ratings, especially with a positive outlook, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100